Related Experiment Videos
Diabetic patients treated with abciximab and intracoronary stenting
Brian L Walton1, Kim Mumm, Megumi Taniuchi
1Barnes-Jewish Hospital and Washington University, St. Louis, Missouri 63110, USA.
Insights
Diabetic patients undergoing angioplasty with stenting may benefit from abciximab, particularly those at higher risk. This drug showed reduced cardiac readmissions in a retrospective study of diabetic patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Diabetology
Background:
- Diabetic patients face increased risks of restenosis, ischemia, and complications after angioplasty.
- Intracoronary stenting is a common procedure, but outcomes can be poorer in diabetic individuals.
Purpose of the Study:
- To evaluate the efficacy and safety of abciximab in diabetic patients undergoing intracoronary stenting.
- To assess the impact of abciximab on clinical outcomes and readmission rates in this high-risk population.
Main Methods:
- Retrospective analysis of 707 diabetic patients treated with intracoronary stents between 1997 and 1999.
- Comparison of outcomes between patients who received abciximab (n=268) and those who did not.
- Analysis of primary endpoints including mortality, revascularization, and myocardial infarction, and secondary endpoint of cardiac readmissions.
Main Results:
- The abciximab group included more patients with severe ventricular dysfunction and high-grade lesions.
- Primary endpoints (mortality, revascularization, myocardial infarction) were similar between groups.
- The abciximab group demonstrated significantly reduced rates of readmission for cardiac reasons across all follow-up periods.
Conclusions:
- Abciximab administration in diabetic patients undergoing intracoronary stenting did not increase adverse primary outcomes.
- Abciximab use was associated with lower cardiac readmission rates in diabetic patients.
- Trends suggest abciximab may offer up to 9 months of benefit for higher-risk diabetic patients, particularly regarding revascularization and cardiac readmissions.
Abstract:
Diabetic patients are at greater risk for restenosis, recurrent ischemia, and complications following angioplasty than are their nondiabetic counterparts. This is a retrospective study identifying diabetic patients who were treated with abciximab and intracoronary stenting during the period of January 1997 to December 1999. Abciximab was administered to 268 of 707 diabetic patients who received intracoronary stents from 1997 to 1999. The abciximab group contained a higher number of patients with severe ventricular dysfunction and high-grade lesions. Primary endpoints of all-cause mortality, same-vessel revascularization, CABG, TVR, and postprocedural myocardial infarction were similar for both groups. The abciximab group had reduced rates of readmission for cardiac reasons during all follow-up periods. The trends toward improvement of mortality, surgical or percutaneous revascularization, and cardiac readmissions suggest the effect of abciximab may provide benefit for up to 9 months for higher-risk diabetic patients.